Inclusion Criteria:  Before neoadjuvant chemotherapy, pancreatic ductal adenocarcinoma was confirmed by pathology; According to the guidelines, neoadjuvant chemotherapy should be performed before surgery, including patients with resectable pancreatic cancer (RPC) with high risk factors, borderline resectable pancreatic cancer (BRPC) with good physical condition, and locally advanced pancreatic cancer (LAPC) with tolerable general condition; Receive at least 2 cycles of neoadjuvant chemotherapy before radical surgery； After neoadjuvant chemotherapy, the patient can be further treated by minimally invasive or open surgery; No obvious surgical contraindications, suitable for minimally invasive surgery; ECOG score of preoperative physical condition was 0-1; No history of preoperative pancreatitis; Preoperative PET-CT or other imaging examination did not show distant metastasis; The expected postoperative survival time was more than 3 months; Be able to comply with research protocol, follow-up plan and other protocol requirements; Voluntary participation and signed informed consent.  Exclusion Criteria:  Neoadjuvant chemotherapy is not suitable before operation according to the guidelines; Invasion of adjacent organs, abdominal cavity or distant metastasis was found by introperative exploration; Patients requiring total pancreatectomy; Severe impairment of heart, liver and kidney function; Patients with other malignancies or hematological diseases; The patient is pregnant, planning to be pregnant or lactating； Before surgery, anti-cancer therapy except neoadjuvant chemotherapy were performed, including interventional chemoembolization, ablation, radiotherapy and molecular targeted therapy; Participants in other clinical trials; Tumor progression occurred in RPC or BRPC patients during neoadjuvant chemotherapy. After neoadjuvant chemotherapy, LAPC patients failed reach the standard of minimally invasive surgery.